ES2686968T3 - Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas - Google Patents

Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas Download PDF

Info

Publication number
ES2686968T3
ES2686968T3 ES14795356.6T ES14795356T ES2686968T3 ES 2686968 T3 ES2686968 T3 ES 2686968T3 ES 14795356 T ES14795356 T ES 14795356T ES 2686968 T3 ES2686968 T3 ES 2686968T3
Authority
ES
Spain
Prior art keywords
leu
gly
wing
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14795356.6T
Other languages
English (en)
Spanish (es)
Inventor
Shuzhen Wang
Yijun Chen
Dongyang HE
Nan Liu
Chao Ma
Zhenyue GAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310162738.3A external-priority patent/CN103214584B/zh
Priority claimed from CN201310163407.1A external-priority patent/CN103232543B/zh
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Application granted granted Critical
Publication of ES2686968T3 publication Critical patent/ES2686968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14795356.6T 2013-05-06 2014-05-05 Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas Active ES2686968T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201310163407 2013-05-06
CN201310162738 2013-05-06
CN201310162738.3A CN103214584B (zh) 2013-05-06 2013-05-06 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN201310163407.1A CN103232543B (zh) 2013-05-06 2013-05-06 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
PCT/CN2014/076768 WO2014180288A1 (zh) 2013-05-06 2014-05-05 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Publications (1)

Publication Number Publication Date
ES2686968T3 true ES2686968T3 (es) 2018-10-23

Family

ID=51866722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14795356.6T Active ES2686968T3 (es) 2013-05-06 2014-05-05 Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas

Country Status (6)

Country Link
US (1) US10875903B2 (https=)
EP (1) EP2995626B1 (https=)
JP (1) JP2016520053A (https=)
DK (1) DK2995626T3 (https=)
ES (1) ES2686968T3 (https=)
WO (1) WO2014180288A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3820887A4 (en) 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
CN116462769A (zh) * 2022-04-02 2023-07-21 广东东阳光药业有限公司 一种嵌合受体及其应用
WO2025217063A1 (en) * 2024-04-08 2025-10-16 Baylor College Of Medicine Dual stimulatory receptors for immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303401A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
CA2331332A1 (en) * 1998-06-17 1999-12-23 Raghuram Kalluri Anti-angiogenic proteins and methods of use thereof
CN100543036C (zh) * 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
EP1771467A2 (en) * 2004-07-26 2007-04-11 Asterion Limited Linkers
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN101265482A (zh) * 2008-04-25 2008-09-17 罗以勤 重组肿瘤抑素-肿瘤坏死因子分泌型真核表达载体及其制备方法和用途
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
JP6047142B2 (ja) 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CN110105453A (zh) * 2011-08-17 2019-08-09 科罗拉多大学董事会法人团体 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法
CN103214584B (zh) * 2013-05-06 2014-07-09 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN103232543B (zh) * 2013-05-06 2014-12-03 中国药科大学 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用

Also Published As

Publication number Publication date
JP2016520053A (ja) 2016-07-11
EP2995626B1 (en) 2018-07-11
DK2995626T3 (en) 2018-10-29
US10875903B2 (en) 2020-12-29
US20200062818A1 (en) 2020-02-27
EP2995626A1 (en) 2016-03-16
EP2995626A4 (en) 2016-11-09
WO2014180288A1 (zh) 2014-11-13

Similar Documents

Publication Publication Date Title
ES2686968T3 (es) Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas
US20200246420A1 (en) pHLIP® peptide-mediated epitope tethering at cell surfaces
CN102153653B (zh) 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
KR101841211B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
WO2018050039A1 (zh) 新的抗pd-1纳米抗体及其应用
WO2013000234A1 (en) A novel recomnimant bifunctional fusion protein and its preparation and use
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
KR20130122764A (ko) 항암 융합 단백질
CN101717449B (zh) 重组TRAIL-Fc融合蛋白及其制备和应用
KR101778244B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
CN104974262B (zh) 重组双功能融合蛋白及其制法和用途
JPH03500415A (ja) インターロイキン２類似体
CN109810946A (zh) 天花粉蛋白用于致敏和/激活树突状细胞中的应用
CN115916831A (zh) 包含抗lag-3抗体和il-2的融合蛋白及其用途
CN102671185A (zh) 少棘蜈蚣多肽毒素omega-SLPTX-Ssm1a的应用
CN101698852B (zh) 具有cd137l功能的蛋白或多肽及其基因和应用
CN101456913B (zh) 一种抗肿瘤融合蛋白及其应用
CN103232543B (zh) 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN106674353B (zh) 一种新的天花粉融合蛋白及其应用
KR101651330B1 (ko) 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도
CN109331177A (zh) 一种免疫增强型多价疫苗及其制备方法和应用
MX2007000115A (es) Hoja de puerta de cristal pivotante alrededor de un quicio superior y uno inferior.
CN103214584B (zh) 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN105985444B (zh) 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
JPH1189582A (ja) 炎症性サイトカイン誘導因子の遺伝子